Long-acting injectable tacrolimus for chronic immunosuppression
Ended Project Grant Awarded Last action
- Award ID
- R44AI170362
- Recipient
-
Auritec Pharmaceuticals, LLC UEI QX8KP6JKQ2L8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,095,228
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- The broad, long-term goal of this direct to phase II sbir is to improve immunosuppression outcomes in organ transplant recipients by developing a long-acting injectable calcineurin inhibitor (CNI). For more than two decades, tacrolimus is a valuable pharmacological tool in the prophylaxis of organ transplant rejection. IT is commercially available as twice and once-daily oral pills. Oral formulations undergo first-pass metabolism and suffer from low and variable bioavailability which in turn leads to high intra- and inter- patient pharmacokinetic (PK) variability. Tacrolimus has a narrow therapeutic index, hence sub-therapeutic blood levels (15 NG/ML) are toxic. Daily dosing has been associated with medication non-adherence. The medical costs transplant recipients with poor adherence are ~$30,000 higher than patients with high adherence at 3 years post-transplant. Thus, the three reported unmet needs are higher medication adherence, better outcomes of graft survival, and linear PK profile. Auritec pharmaceuticals has developed a subcutaneous injectable formulation of tacrolimus that provides consistent therapeutic blood levels of the drug for 30 days after a single administration. The product is based on auritec's innovative plexis technology that has shown clinical proof of concept in two phase 1 trials. The plexis technology is differentiated from other long-acting injectable technologies in terms of its high drug loading, scalable manufacturing process, and more linear release kinetics. The product has demonstrated safe and sustained release of tacrolimus in a first-in-human safety/PK study using the "exploratory IND" approach. PK modeling shows that a monthly dosing schedule can be readily achieved in transplant recipients to maintain tacrolimus blood levels in the safe and efficacious range (5-15 NG/ML). The benefits of our product include 1) complete medication adherence for 1 month after one administration; 2) fewer episodes of graft rejections; 3) simpler dosing schedule, and; 4) a smooth PK profile without sub- or supra-therapeutic levels. The populations anticipated to benefit from the product are: patients who have demonstrated tolerability to tacrolimus but find IT challenging to adhere to a daily fixed schedule (such as younger patients) and/or rapid metabolizers of tacrolimus. The end result will be a cost-effective maintenance therapy for maintenance therapy. The specific aims of this direct to phase II sbir are to perform activities in pursuit of a "traditional phase 1 IND" allowance. The proposed work includes - manufacturing in accordance with current good manufacturing practices (cgmp); animal testing in compliance with good laboratory practices (GLP); analytical method development; chemistry, manufacturing and controls (CMC) testing; and finally, IND submission to the FDA. These efforts will result in an IND approval and allow for the first-in-human testing of safety, PK, and preliminary efficacy in transplant recipients. Successful completion of this work will further DE-risk the product by bringing IT closer to clinical testing and making IT attractive to investors.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,023,600 | |
| Amendment | $1,023,600 | |
| Amendment | $1,024,014 | |
| Original award | $1,024,014 |
Quick answers
Who received award R44AI170362?
R44AI170362 was awarded to Auritec Pharmaceuticals, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 8, 2022.
How much is award R44AI170362 worth?
$4,095,228 has been obligated on R44AI170362.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award